Forget everything you've heard about the benefits of Tamiflu, the Roche corporation's blockbuster influenza drug. A new analysis that includes previously-unpublished trials offers a fresh, and very unflattering, perspective.
Selective publication, in which some trials of a drug are released publicly and others are not, is widely considered unethical....
(31) Comments | Posted May 5, 2015 | 10:38 AM